Engineered EVs have been shown to serve as a functional collagen replacement therapy in preclinical models by delivering COL1A1 mRNA to induce collagen formation, and a similar approach could plausibly be used to deliver functional COL7A1 mRNA to RDEB patients [77]. The gene discussed is COL7A1; the disease is recessive dystrophic epidermolysis bullosa.